Cutaneous lymphoid perivascular reaction with atypical CD30+ T cells in a patient with multiple myeloma treated with bortezomib.
Dehesa
L
L
Bastida
J
J
Limeres-González
M
M
Campos-Adsuar
C
C
Gómez-Duaso
J
J
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001897:Boronic Acids / Q000009:adverse effects*; D000069286:Bortezomib; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D006801:Humans; D017730:Ki-1 Antigen / Q000276:immunology*; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000276:immunology; D011719:Pyrazines / Q000009:adverse effects*; D016176:T-Lymphocyte Subsets / Q000276:immunology*
D000970:Antineoplastic Agents; D001897:Boronic Acids; D017730:Ki-1 Antigen; D011719:Pyrazines; D000069286:Bortezomib